09:13 AM EDT, 05/31/2024 (MT Newswires) -- Pfizer ( PFE ) said Friday that longer-term follow-up results from the phase 3 CROWN trial showed benefits of Lorbrena over Xalkori for previously untreated, anaplastic lymphoma kinase-positive advanced non-small cell lung cancer patients.

After five years of median follow-up, Lorbrena demonstrated an 81% reduction in disease progression or death compared to Xalkori, with 60% of patients remaining progression-free versus 8% with Xalkori, the company said. Additionally, Lorbrena reduced the risk of intracranial progression by 94%, according to the company.

Shares of Pfizer ( PFE ) were up 0.2% in Friday premarket activity.

Price: 28.29, Change: +0.09, Percent Change: +0.31